# Evaluation of Ingenol Mebutate for Actinic Cheilitis Treatment

> **NCT03452566** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Instituto Nacional de Cancer, Brazil**

## Conditions studied

- Actinic Cheilitis

## Interventions

- **DRUG:** Ingenol mebutate gel

## Key facts

- **NCT ID:** NCT03452566
- **Lead sponsor:** Instituto Nacional de Cancer, Brazil
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-02
- **Primary completion:** 2021-09
- **Final completion:** 2022-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Ingenol mebutato discontinued in Brazil.
- **Last updated:** 2019-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03452566

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03452566, "Evaluation of Ingenol Mebutate for Actinic Cheilitis Treatment". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03452566. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*